A First Report on [F-18] FPRGD(2) PET/CT Imaging in Multiple Myeloma

作者：Withofs Nadia; Cousin Francois; De Prijck Bernard; Bonnet Christophe; Hustinx Roland; Gambhir Sanjiv S; Beguin Yves; Caers Jo^*

来源：Contrast Media and Molecular Imaging, 2017, 2017: UNSP 6162845.

DOI：10.1155/2017/6162845

An observational study was set up to assess the feasibility of [F-18] FPRGD 2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [F-18] NaF/[F-18] FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole- body PET/CT after injection of [F-18] FPRGD 2. The obtained images were compared with results of low dose CT and already available results of a combined [F-18] NaF/[F-18] FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [F-18] FPRGD 2 PET/CT compared to low dose CT (98%) or [F-18] NaF/[F-18] FDG PET/CT (70%) and all FLs detected with [F-18] FPRGD 2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [F-18] FPRGD 2 positive lesions were seen than [F-18] NaF/[F-18] FDG positive lesions. This study suggests that [F-18] FPRGD 2 PET/CT might be less useful for the detection ofmyeloma lesions in patients with advanced disease as all FLs with [F-18] FPRGD 2 uptake were already detected with CT alone.

• 出版日期2017